Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonidegib + etoposide + cisplatin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sonidegib (LDE225) is a selective oral small molecule inhibitor of Smoothened, a key component of the Hedgehog signaling pathway. Etoposide is a topoisomerase 2A inhibitor that interferes with DNA replication and cell division. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in cancer cells. The combination of sonidegib with etoposide and cisplatin has been investigated in clinical trials for extensive-stage small cell lung cancer (ES-SCLC). Sonidegib targets tumor growth driven by aberrant Hedgehog pathway activation; etoposide and cisplatin are standard first-line cytotoxic agents for SCLC[1][2][6].
- Brand names
- Odomzo
- Other names
- EP regimen
02
Targets
DNASMO (Smoothened)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on sonidegib + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonidegib + etoposide + cisplatin.